📣 VC round data is live. Check it out!

TransMedics Valuation Multiples

Discover TransMedics' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Sinbon Electronics, Double Medical Technology, Insight Lifetech, Elekta and more.

TransMedics Overview

About TransMedics

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.


Founded

2018

HQ

United States

Employees

898

Financials (LTM)

Revenue: $659M
EBITDA: $159M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

TransMedics Financials

TransMedics reported last 12-month revenue of $659M and EBITDA of $159M.

In the same LTM period, TransMedics generated $393M in gross profit, $159M in EBITDA, and $142M in net income.

Revenue (LTM)


TransMedics P&L

In the most recent fiscal year, TransMedics reported revenue of $605M and EBITDA of $163M.

TransMedics is profitable as of last fiscal year, with gross margin of 60%, EBITDA margin of 27%, and net margin of 31%.

See analyst estimates for TransMedics
LTMLast FY202320242025202620272028
Revenue$659M$605M$242M$442M$605M
Gross Profit$393M$363M$154M$262M$363M
Gross Margin60%60%64%59%60%
EBITDA$159M$163M($8M)$70M$148M
EBITDA Margin24%27%(3%)16%25%
EBIT Margin16%18%(12%)8%18%
Net Profit$142M$190M($25M)$35M$190M
Net Margin22%31%(10%)8%31%
Net Debt-$24M---

Financial data powered by Morningstar, Inc.

TransMedics Stock Performance

TransMedics has current market cap of $2B, and enterprise value of $3B.

Market Cap Evolution


TransMedics' stock price is $68.45.

TransMedics share price increased by 1.9% in the last 30 days, and decreased by 48.9% in the last year.

TransMedics has an EPS (earnings per share) of $5.51.

See more trading valuation data for TransMedics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$2B1.4%1.9%-31.1%-48.9%$5.51

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

TransMedics Valuation Multiples

TransMedics trades at 4.2x EV/Revenue multiple, and 17.4x EV/EBITDA.

See NTM and 2027E valuation multiples for TransMedics

EV / Revenue (LTM)


TransMedics Financial Valuation Multiples

As of June 3, 2026, TransMedics has market cap of $2B and EV of $3B.

TransMedics has a P/E ratio of 16.7x.

LTMLast FY202320242025202620272028
EV/Revenue4.2x4.6x11.5x6.3x4.6x
EV/EBITDA17.4x17.0xn/m39.6x18.6x
EV/EBIT26.1x25.5x(96.3x)73.8x25.5x
EV/Gross Profit7.0x7.6x18.0x10.6x7.6x
P/E16.7x12.4x(94.5x)66.7x12.4x
EV/FCF30.8x16.3x(14.4x)(34.2x)20.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified TransMedics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

TransMedics Margins & Growth Rates

TransMedics grew revenue by 21% but EBITDA decreased by 5% in the last fiscal year.

In the most recent fiscal year, TransMedics reported gross margin of 60%, EBITDA margin of 27%, and net margin of 31%.

See estimated margins and future growth rates for TransMedics

TransMedics Margins

Last FY202420252026202720282029
Gross Margin60%59%60%59%
EBITDA Margin27%16%25%21%
EBIT Margin18%8%18%14%
Net Margin31%8%31%10%
FCF Margin28%(18%)22%(3%)

TransMedics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth21%83%37%21%
Gross Profit Growth20%70%38%20%
EBITDA Growth(5%)(1008%)112%4%
EBIT Growth(6%)(231%)190%(6%)
Net Profit Growth(60%)(242%)437%(60%)
FCF Growth(111%)(58%)(265%)(114%)

Data powered by FactSet, Inc. and Morningstar, Inc.

TransMedics Operational KPIs

TransMedics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.

TransMedics' Rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TransMedics' Rule of X is 74% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for TransMedics
LTMLast FY202320242025202620272028
Rule of 4044%42%---
Bessemer Rule of X74%74%---
Revenue per Employee-$0.7M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue-1%2%1%1%
G&A Expenses to Revenue-30%48%37%30%
R&D Expenses to Revenue12%11%26%13%11%
Opex to Revenue-42%76%51%42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

TransMedics Competitors

TransMedics competitors include Sinbon Electronics, Double Medical Technology, Insight Lifetech, Elekta, Tecan Group, GN Store Nord, Jeol, Jafron Biomedical, Axogen and LeMaitre Vascular.

Most TransMedics public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sinbon Electronics2.3x2.3x15.9x17.6x
Double Medical Technology5.9x5.6x16.4x13.9x
Insight Lifetech29.2x-131.6x-
Elekta1.5x1.5x11.4x10.8x
Tecan Group2.1x2.1x14.0x13.9x
GN Store Nord1.4x1.6x8.8x9.5x
Jeol1.7x1.9x11.2x10.5x
Jafron Biomedical6.5x6.3x13.3x13.2x

This data is available for Pro users. Sign up to see all TransMedics competitors and their valuation data.

Start Free Trial

TransMedics VC Funding History

Before going public, TransMedics raised $84M in total equity funding, across 4 rounds.


TransMedics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-16Series AAbrams Capital; BioStar Capital; Fayerweather Fund; Flagship Pioneering; Inbio Ventures; Kleiner Perkins; Lung Biotechnology; Pharmstandard$13M--
May-16Series FAbrams Capital; BioStar Capital; Fayerweather Fund; Flagship Pioneering; Inbio Ventures; Kleiner Perkins; Lung Biotechnology; Millhouse$51M-TransMedics is a medical technology company developing organ transplant therapy solutions, including its Organ Care System (OCS) platform to improve organ preservation and transplant outcomes.
Sep-15Pre-seed-$500K--
Jun-15Undisclosed stage-$20M-TransMedics, based in Andover, Mass., develops the Organ Care System (OCS), a technology designed to perfuse donor organs with warm, oxygenated blood and monitor their status until transplantation, targeting heart, lung, and liver organs. In 2015, the company expanded a $51.2 million equity funding round closed in May by adding $12.5 million, bringing the total raise to over $63.7 million, as announced around July. The round was co-led by Fayerweather Fund and Pharmstandard International S.A. (via InBio Ventures), with participation from Ervington Investments, BioStar Ventures, and existing investors including Abrams Capital, Lung Biotechnology PBC, Flagship Ventures, and Kleiner Perkins Caufield & Byers (KPCB), involving a total of 20 investors per SEC filing. This financing aimed to position TransMedics to capitalize on market opportunities in organ transplantation. Around April 2015, TransMedics published results from the Proceed II study in The Lancet, demonstrating non-inferiority of its OCS Heart device compared to traditional cold static storage for 30-day patient and graft survival (94% vs. 97%) in 130 heart transplant patients. In February 2015, the company launched a pivotal study for its OCS Liver device. The FDA decided no advisory panel was needed for the heart preservation device PMA review.

Acquisitions by TransMedics

TransMedics has acquired 1 company to date.

Last acquisition by TransMedics was on August 1st 2023. TransMedics acquired Summit Aviation for $18M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by TransMedics

Summit Aviation
Description
Summit Aviation is a Greenwich, Connecticut-based charter and aircraft management company that operates a fleet including Cessna Citations, Gulfstream jets, and single-engine pistons. The firm provides Part 135 charter services, FBO operations at Essex County Airport, and maintenance for business and leisure flights across the Northeast United States.
HQ CountryUnited States
HQ City
-
Deal Date1 Aug 2023
Valuation$18M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all TransMedics acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by TransMedics

TransMedics has invested in 1 company to date.

Latest investment by TransMedics was on April 28th 2026. TransMedics invested in Padaviation in their Strategic investment round.

See VC round multiples

Latest Investments by TransMedics

Padaviation
Description
Padaviation is an airline providing private air charter and travel services.
HQ CountryGermany
HQ City
Bühren
Deal Date28 Apr 2026
RoundStrategic investment
Raisedundisclosed
InvestorsTransMedics
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all TransMedics investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About TransMedics

When was TransMedics founded?TransMedics was founded in 2018.
Where is TransMedics headquartered?TransMedics is headquartered in United States.
How many employees does TransMedics have?As of today, TransMedics has over 898 employees.
Who is the CEO of TransMedics?TransMedics' CEO is Waleed H. Hassanein.
Is TransMedics publicly listed?Yes, TransMedics is a public company listed on Nasdaq.
What is the stock symbol of TransMedics?TransMedics trades under TMDX ticker.
When did TransMedics go public?TransMedics went public in 2019.
Who are competitors of TransMedics?TransMedics main competitors include Sinbon Electronics, Double Medical Technology, Insight Lifetech, Elekta, Tecan Group, GN Store Nord, Jeol, Jafron Biomedical, Axogen, LeMaitre Vascular.
What is the current market cap of TransMedics?TransMedics' current market cap is $2B.
What is the current revenue of TransMedics?TransMedics' last 12 months revenue is $659M.
What is the current revenue growth of TransMedics?TransMedics revenue growth (NTM/LTM) is 20%.
What is the current EV/Revenue multiple of TransMedics?Current revenue multiple of TransMedics is 4.2x.
What is the current EBITDA of TransMedics?TransMedics' last 12 months EBITDA is $159M.
What is TransMedics' EBITDA margin?TransMedics' last 12 months EBITDA margin is 24%.
What is the current EV/EBITDA multiple of TransMedics?Current EBITDA multiple of TransMedics is 17.4x.
What is the current FCF of TransMedics?TransMedics' last 12 months FCF is $90M.
What is TransMedics' FCF margin?TransMedics' last 12 months FCF margin is 14%.
What is the current EV/FCF multiple of TransMedics?Current FCF multiple of TransMedics is 30.8x.
How many companies TransMedics has acquired to date?As of June 2026, TransMedics has acquired 1 company.
What was the largest acquisition by TransMedics?$18M acquisition of Summit Aviation on 1st August 2023 was the largest M&A TransMedics has done to date.
What companies TransMedics acquired?TransMedics acquired Summit Aviation.
In how many companies TransMedics has invested to date?As of June 2026, TransMedics has invested in 1 company.
What was the last TransMedics investment?On 28th April 2026 TransMedics invested in Padaviation, participating in a Strategic investment round.
In what companies TransMedics invested in?TransMedics invested in Padaviation.

See public comps similar to TransMedics

Lists including TransMedics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial